Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GLEN ALLEN, VA., AUG. 14, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

ADIAL PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MEETING COMPLETION MARKS MAJOR STEP TOWARD PHASE 3 AD04 TRIAL LAUNCH STRATEGIC PARTNERSHIP DISCUSSIONS EXPECTED FOLLOWING THE POSITIVE FDA MEETING GLEN ALLEN, VA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THE COMPLETION OF A SUCCESSFUL END OF PHASE 2 MEETING (EOP2M) WITH THE FOOD AND DRUG ADMINISTRATION (FDA).

ADIAL PHARMACEUTICALS COMPLETES SUCCESSFUL EOP2 FDA MEETING

GLEN ALLEN, VA., JULY 16, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THAT IT RECEIVED NOTICE FROM NASDAQ ON JULY 14, 2025 THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(B)(1), WHICH REQUIRES LISTED COMPANIES TO MAINTAIN STOCKHOLDERS' EQUITY OF AT LEAST$2,500,000.

ADIAL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ STOCKHOLDERS' EQUITY LISTING REQUIREMENT

GLEN ALLEN, VA., JULY 09, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, ANNOUNCED THE FILING OF AN UPDATE TO THE PROVISIONAL PATENT APPLICATION FOR AD04 WHICH WAS FILED IN JULY 2024, THE COMPANY'S LEAD INVESTIGATIONAL GENETICALLY TARGETED, SEROTONIN-3 RECEPTOR ANTAGONIST, THERAPEUTIC AGENT FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD) IN HEAVY DRINKING PATIENTS (DEFINED AS < 10 DRINKS/DRINKING DAY).

ADIAL PHARMACEUTICALS FILES PCT PATENT APPLICATION TO PROTECT CORE ASSETS AND EXTEND IP EXCLUSIVITY ON CORE TECHNOLOGY TO AT LEAST 2045

SCOPE OF AGREEMENT WITH CAMBREX TO PROVIDE ONDANSETRON HCL DRUG SUBSTANCE UNDER FDA APPROVED DRUG MASTER FILE SCOPE OF AGREEMENT WITH THERMO FISHER TO PROVIDE MANUFACTURING SERVICES INCLUDING DEMONSTRATION, CLINICAL, REGISTRATION AND VALIDATION BATCHES OF AD04 FOR US CLINICAL TRIALS AND NDA SUBMISSION GLEN ALLEN, VA., JUNE 25, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THE RECENT EXECUTION OF AGREEMENTS FOR THE PRODUCTION OF AD04 (0.33 MG ONDANSETRON TABLETS), SUPPORTING BOTH THE COMPLETION OF UPCOMING CLINICAL TRIALS AND THE PLANNED NEW DRUG APPLICATION (NDA) SUBMISSION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD) IN THE US.

ADIAL PHARMACEUTICALS SECURES U.S.-BASED MANUFACTURING THROUGH AGREEMENTS WITH CAMBREX AND THERMO FISHER SCIENTIFIC FOR DRUG SUBSTANCE AND DRUG PRODUCT SUPPLY

GLEN ALLEN, VA., MAY 15, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025.

ADIAL PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MILESTONE ACHIEVED AS ADOVATE INITIATES FIRST-IN-HUMAN STUDY FOR NOVEL ASTHMA THERAPY TARGETING UNDERSERVED, MULTI-BILLION DOLLAR MARKET MILESTONE ACHIEVED AS ADOVATE INITIATES FIRST-IN-HUMAN STUDY FOR NOVEL ASTHMA THERAPY TARGETING UNDERSERVED, MULTI-BILLION DOLLAR MARKET

ADIAL PHARMACEUTICALS RECEIVES MILESTONE PAYMENT FROM ADOVATE FOLLOWING INITIATION OF PHASE 1 STUDY

GLEN ALLEN, VA., MAY 02, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED ITS ENTRY INTO A WARRANT INDUCEMENT AGREEMENT WITH AN EXISTING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR OF THE COMPANY FOR THE IMMEDIATE EXERCISE OF EXISTING SERIES B WARRANTS (THE "SERIES B WARRANTS") TO PURCHASE UP TO 1,418,440 SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE (THE COMMON STOCK), AND SERIES C WARRANTS (THE "SERIES C WARRANTS", AND TOGETHER WITH THE SERIES B WARRANTS THE "EXISTING WARRANTS") TO PURCHASE UP TO 2,300,000 SHARES OF COMMON STOCK AT A REDUCED EXERCISE PRICE OF $0.74 FOR GROSS CASH PROCEEDS OF APPROXIMATELY $2.75 MILLION, BEFORE DEDUCTING FINANCIAL ADVISOR FEES AND OTHER TRANSACTION EXPENSES. THE COMPANY INTENDS TO USE THE NET PROCEEDS FROM THE OFFERING FOR WORKING CAPITAL AND OTHER GENERAL CORPORATE PURPOSES.

ADIAL PHARMACEUTICALS ANNOUNCES A WARRANT INDUCEMENT TRANSACTION FOR $2.75 MILLION IN GROSS PROCEEDS

NEW PATENT COVERS A TREATMENT METHOD FOR A BROAD SPECTRUM OF ALCOHOL-RELATED DISORDERS, INCLUDING ADDITIONAL CONDITIONS ASSOCIATED WITH ALCOHOL USE NEW PATENT COVERS A TREATMENT METHOD FOR A BROAD SPECTRUM OF ALCOHOL-RELATED DISORDERS, INCLUDING ADDITIONAL CONDITIONS ASSOCIATED WITH ALCOHOL USE

ADIAL PHARMACEUTICALS EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH NEW U.S. PATENT GRANTED FOR GENETIC-BASED TREATMENT OF ALCOHOL AND OPIOID USE DISORDERS

GLEN ALLEN, VA., MARCH 04, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE 2024 FISCAL YEAR ENDED DECEMBER 31, 2024.

ADIAL PHARMACEUTICALS REPORTS 2024 FISCAL YEAR FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FDA FEEDBACK CONFIRMS ADIAL'S PROPOSED IN VITRO BRIDGING STRATEGY TO THE PHASE 3 FORMULATION TO FULFILL THE BRIDGING REQUIREMENT FOR THE 505(B)(2) REGULATORY REGISTRATION PATHWAY FOR APPROVAL

Adial Pharmaceuticals, Inc.

ADIL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Adial Pharmaceuticals, Inc.

ADIL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ADIL